Gan&Lee Pharmaceuticals (603087.SH) Receives El Salvador Drug Registration Approval for Insulin Glargine Injection (Cartridge)

Gan & Lee Pharmaceuticals Gets El Salvador Approval for Insulin Glargine Pen

Gan & Lee Doses First Subject in Phase 1 Clinical Trial of Low Blood Protein Injection

Gan&Lee Pharmaceuticals Secures Drug Registration Approval in El Salvador for Insulin Glargine Injection (Prefilled Pen)

Gan & Lee Pharmaceuticals Gets Ethiopia Approval for Insulin Aspart Injection

Gan&Lee Pharmaceuticals Receives Ethiopian Drug Registration Approval for Insulin Aspart Injection

Gan & Lee Pharmaceuticals Gets China Approval for GLR1075 Clinical Trial; Shares Up 3%

Gan & Lee Pharmaceuticals Receives Clinical Trial Approval for Investigational Drug GLR1075 Injection

First Participant Dosed in First-in-Human Phase 1 Study of Gzc8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide Glp-1 Ra

Gan & Lee Pharmaceuticals Doses First Subject in Weight Loss Drug Trial

Gan&Lee Pharmaceuticals Begins Phase I Dosing in GZC8072 Obesity and Diabetes Study

Executive Share Sales and Shifting Financial Strategies Test Gan&Lee's Transformation Path

Gan & Lee Pharma Gets China Nod for Diabetes, Obesity Drug Trial

Gan & Lee Pharmaceuticals: Co & Menarini Group to Collaborate on Registration, Commercialization of Co's Bofanglutide

Gan & Lee and Menarini Group Partner to Advance Bofanglutide in Europe

Gan & Lee Pharmaceuticals: Aggregate Potential Deal Value is up to EUR 726Million, Excluding Royalties.

Gan & Lee Pharmaceuticals: Co Eligible to Receive Upfront Payment of EUR 62 Mln , Milestone Payments Totaling up to EUR 664 Mln

Gan&Lee Receives Clinical Trial Approval for GZC8072 Tablet in New Indication

Gan & Lee Pharma's H1 Profit Rises 1%, Revenue Climbs 8%

Gan & Lee Pharmaceuticals H1 Net Profit up 1.01% Y/Y